Industry Strength Score
32/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CARDIOL THERAPEUTICS INC-A (CRDL.CA) Stock Price & Overview
TSX:CRDL • CA14161Y2006
Current stock price
1.84 CAD
-0.02 (-1.08%)
Last:
The current stock price of CRDL.CA is 1.84 CAD. Today CRDL.CA is down by -1.08%. In the past month the price decreased by -7.07%. In the past year, price increased by 17.2%.
CRDL.CA Key Statistics
52-Week Range1.225 - 2.33
Current CRDL.CA stock price positioned within its 52-week range.
1-Month Range1.76 - 2.33
Current CRDL.CA stock price positioned within its 1-month range.
- Market Cap
- 205.749M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.39
- Dividend Yield
- N/A
CRDL.CA Stock Performance
Today
-1.08%
1 Week
-2.65%
1 Month
-7.07%
3 Months
+43.75%
Longer-term
6 Months +19.48%
1 Year +17.20%
2 Years -48.46%
3 Years +102.20%
5 Years -43.03%
10 Years N/A
CRDL.CA Stock Chart
CRDL.CA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CRDL.CA. When comparing the yearly performance of all stocks, CRDL.CA is one of the better performing stocks in the market, outperforming 74.54% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CRDL.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRDL.CA. CRDL.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CRDL.CA Earnings
Next Earnings DateMay 19, 2026
Last Earnings DateApr 1, 2026
PeriodQ4 / 2025
EPS Reported-CA$0.07
Revenue Reported
EPS Surprise 14.22%
Revenue Surprise %
CRDL.CA Forecast & Estimates
8 analysts have analysed CRDL.CA and the average price target is 8.66 CAD. This implies a price increase of 370.4% is expected in the next year compared to the current price of 1.84.
Analysts
Analysts82.5
Price Target8.66 (370.65%)
EPS Next Y-36%
Revenue Next YearN/A
CRDL.CA Financial Highlights
Over the last trailing twelve months CRDL.CA reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS increased by 23.53% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-33.82M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -143.18% | ||
| ROE | -189.17% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%22.22%
Sales Q2Q%N/A
EPS 1Y (TTM)23.53%
Revenue 1Y (TTM)N/A
CRDL.CA Ownership
Ownership
Inst Owners20.19%
Shares111.82M
Float107.54M
Ins Owners3.83%
Short Float %N/A
Short RatioN/A
CRDL.CA Industry Overview
CRDL.CA operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 30 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
46/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
28%
Outperformed 28% of sub-industries
3 Month Rank
64%
Outperformed 64% of sub-industries
6 Month Rank
28%
Outperformed 28% of sub-industries
Industry Fundamentals & Breadth
- Members
- 30
- New Highs
- 3.3%
- New Lows
- 10%
- Average ROE
- 17.4%
- Average Profit Margin
- 31.5%
- Average Operating Margin
- 20.4%
- Average P/E
- 5.1
- Average Fwd P/E
- 16.7
- Average Debt/Equity
- 0.5
CRDL.CA Competitors/Peers
The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.3 | 2.864B | ||
| CRON | CRONOS GROUP INC | 39.84 | 1.358B | ||
| TLRY | TILRAY BRANDS INC | N/A | 976.689M | ||
| DHT-UN | DRI HEALTHCARE TRUST | 5.23 | 899.577M | ||
| GUD | KNIGHT THERAPEUTICS INC | 43.97 | 740.127M | ||
| WEED | CANOPY GROWTH CORP | N/A | 692.938M | ||
| DHT-U | DRI HEALTHCARE TRUST | 3.86 | 643.734M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 17.37 | 451.501M | ||
| TSND | TERRASCEND CORP | N/A | 379.358M | ||
| HITI | HIGH TIDE INC | 15.7 | 292.707M | ||
| ACB | AURORA CANNABIS INC | 58.42 | 267.671M | ||
| OGI | ORGANIGRAM GLOBAL INC | 28.31 | 263.136M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About CRDL.CA
Company Profile
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company is headquartered in Oakville, Ontario and currently employs 18 full-time employees. The company went IPO on 2018-12-20. The firm's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The firm is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Company Info
IPO: 2018-12-20
CARDIOL THERAPEUTICS INC-A
602-2265 Upper Middle Road East
Oakville ONTARIO L6H 0G5 CA
CEO: David G. Elsley
Employees: 18
Phone: 12899100850
CARDIOL THERAPEUTICS INC-A / CRDL.CA FAQ
What does CARDIOL THERAPEUTICS INC-A do?
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company is headquartered in Oakville, Ontario and currently employs 18 full-time employees. The company went IPO on 2018-12-20. The firm's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The firm is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
What is the stock price of CARDIOL THERAPEUTICS INC-A today?
The current stock price of CRDL.CA is 1.84 CAD. The price decreased by -1.08% in the last trading session.
Does CRDL stock pay dividends?
CRDL.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of CRDL stock?
CRDL.CA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CRDL stock?
CRDL.CA stock is listed on the Toronto Stock Exchange exchange.
What is the Price/Earnings (PE) ratio of CARDIOL THERAPEUTICS INC-A (CRDL.CA)?
CARDIOL THERAPEUTICS INC-A (CRDL.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.39).
What is the market capitalization of CRDL stock?
CARDIOL THERAPEUTICS INC-A (CRDL.CA) has a market capitalization of 205.75M CAD. This makes CRDL.CA a Micro Cap stock.